Physician profile
George E Roque
NPI 1376505834
$11,457.59
in general payments reported to CMS, 2019-2025
48 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,836 · 2020: $1,336 · 2021: $2,264 · 2022: $1,669 · 2023: $1,778 · 2024: $1,268 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,352.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,688.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $958.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $823.82 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $787.76 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $629.01 | 2021-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $573.37 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $571.72 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $548.73 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $539.09 | 2019-2025 | |
| Pfizer INC. | $503.24 | 2019-2025 | |
| Amgen INC. | $442.00 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $367.13 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $301.57 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $248.04 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $237.17 | 2019-2025 | Gattex |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $224.24 | 2019-2022 | |
| Abbott Laboratories | $219.35 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Exact Sciences Corporation | $190.27 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $183.45 | 2019-2023 | Veozah |
| Amarin Pharma, INC. | $143.30 | 2019-2022 | |
| Lundbeck LLC | $130.44 | 2023-2025 | Rexulti |
| Allergan, INC. | $107.88 | 2019-2020 | |
| Eisai INC. | $105.09 | 2020-2022 | |
| Daiichi Sankyo INC. | $93.55 | 2020-2021 | |
| Corcept Therapeutics | $87.52 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $86.01 | 2019-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company Ltd. | $81.43 | 2022 | |
| Ethicon US, LLC | $58.74 | 2020 | |
| Dexcom, INC. | $57.64 | 2021-2022 | |
| Radius Health, INC. | $54.61 | 2019-2020 | |
| Almatica Pharma LLC | $50.24 | 2022-2024 | Teriparatide |
| Medtronic, INC. | $39.91 | 2021-2025 | Intellis Adaptivestim |
| Sunovion Pharmaceuticals INC. | $37.38 | 2021 | |
| Inspire Medical Systems, INC. | $29.87 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $27.99 | 2021-2024 | Livalo |
| Merck Sharp & Dohme LLC | $26.09 | 2019-2021 | |
| Shield Therapeutics INC | $25.16 | 2023 | Accrufer |
| Vanda Pharmaceuticals INC. | $20.93 | 2024 | Fanapt |
| Genentech USA, INC. | $18.70 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.89 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $16.87 | 2022 | |
| Tris Pharma INC | $16.50 | 2024 | Dyanavel Xr |
| Ge Healthcare | $16.39 | 2019 | |
| Boston Scientific Corporation | $16.14 | 2025 | Watchman Flx |
| Corium, LLC | $15.63 | 2022 | |
| Philips North America LLC | $13.71 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.87 | 2020 | |
| Cardiovascular Systems INC. | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Roque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.